1 / 16

Shao-Liang Chen, MD, FACC

Pulmonary artery denervation for treatment of pulmonary arterial hypertension: results from a controlled before and after study—PADN 2 study. Shao-Liang Chen, MD, FACC. Disclosure. I, Shao-Liang Chen, has nothing to disclosure. Background: surgical denervation.

manualh
Download Presentation

Shao-Liang Chen, MD, FACC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pulmonary artery denervation for treatment of pulmonary arterial hypertension: results from a controlled before and after study—PADN 2 study Shao-Liang Chen, MD, FACC

  2. Disclosure I, Shao-Liang Chen, has nothing to disclosure

  3. Background: surgical denervation Juratsch CE, et al. Chest 1980;77;525-530

  4. Background: percutaneou denervation PADN at PA bifurcation, followed by PADN PADN at distal PA, followed by PADN Chen SL, et al. Eurointervention 2013 March

  5. Background: PADN-1 FIM study 22 patients unresponsive to medication enrolled between March and May 2012 1 patientexcluded: (+) adenosine test 21 patients PADN group(N=13) Control group(N=8) 3-month follow-up: 6MWT, echo, Hemodynamic measurements: post, 24h,1w,3-m Chen SL, et al. JACC 2013;61:1482-1488

  6. Primary endpoint Primary endpoint: Δ6-minute walk distance (6MWD) at 6-month follow-up between PADN and Medication groups Definition: Δ6MWD =6MWD-6-month minus 6MWD-baseline

  7. Secondary endpoints Hemodynamic variables: mean and systolic pulmonary arterial pressure pulmonary vessel resistance RV function (Tei) PAH-related events, repeat hospitalization

  8. Definition of PAH-related events the worsening of PAH, the initiation of treatment with the intravenous or subcutaneous injection of drugs, lung transplantation, atrial septostomy all-cause death

  9. Calculation of sample size Patient sample size: Δ6MWD =+60 m after PADN treatment Δ6MWD= +15 m after the medication treatment A total of 24 patients were required 15% of additional sample (uncertainty), finally N=28 patients To achieve 2-sided p-value<0.05, 80% power

  10. Study flow chart Target drugs= 5’-PDE Prostacyclin ET-receptor antagonists

  11. Baseline clinical characteristics

  12. Medication treatment

  13. Comparison of measurements

  14. In conclusion PADN treatment was associated with significant improvement of 6MWD and less PAH-related event Further RCT was required to show the benefit of PADN in reducing mortality in patients with IPAH, secondary PAH and PH from LHD

  15. Thanks for your attention !

More Related